Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus

Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994

1998 • 2,780 citations

Pathogenesis of NIDDM: A Balanced Overview

1992 • 2,111 citations

The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010

1997 • 1,777 citations

Pharmacologic Therapy for Type 2 Diabetes Mellitus

1999 • 1,196 citations

Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application

2000 • 991 citations

RIBBONS 2.0

1991 • 814 citations

Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study.

1992 • 736 citations

Economic Consequences of Diabetes Mellitus in the U.S. in 1997

1998 • 642 citations

Quantitation of Hepatic Glycogenolysis And Gluconeogenesis in Fasting Humans With ¹³ C NMR

1991 • 515 citations

Contributions of gluconeogenesis to glucose production in the fasted state.

1996 • 470 citations

Implications of the United Kingdom Prospective Diabetes Study

2003 • 412 citations

Specific features of glycogen metabolism in the liver

1998 • 394 citations

The Family of Glycogen Phosphorylases: Structure and Functio

1989 • 386 citations

Diabetes in America, 2nd edition

1995 • 321 citations

Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

2000 • 316 citations

Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting.

1999 • 281 citations

Interleukin-6 gene polymorphism and insulin sensitivity.

2000 • 249 citations

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo

1998 • 227 citations

Role of Liver in Pathophysiology of NIDDM

1992 • 209 citations

Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease

1999 • 190 citations

Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study.

1997 • 186 citations

Hyperglycemic Crises in Patients With Diabetes Mellitus

2001 • 171 citations

The role of the liver in metabolic homeostasis: Implications for inborn errors of metabolism

1991 • 156 citations

A new allosteric site in glycogen phosphorylase b as a target for drug interactions

2000 • 130 citations

Perspective: The Insulin Signaling System—A Common Link in the Pathogenesis of Type 2 Diabetes

2000 • 129 citations

Flavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site

2000 • 125 citations

Human liver glycogen phosphorylase inhibitors bind at a new allosteric site

2000 • 122 citations

Design of Inhibitors of Glycogen Phosphorylase: A Study of .alpha.- and .beta.-C-Glucosides and 1-Thio-.beta.-D-glucose Compounds

1994 • 120 citations

Synergistic regulation of phosphorylase a by glucose and caffeine.

1978 • 113 citations

Glucose and glycogen utilisation in myocardial ischemia--changes in metabolism and consequences for the myocyte.

1998 • 110 citations

Glucose analog inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes

1991 • 109 citations

Inhibition of glycogenolysis in primary rat hepatocytes by 1,4-dideoxy-1,4-imino-D-arabinitol

1999 • 108 citations

Glucose production, recycling, and gluconeogenesis in normals and diabetics: a mass isotopomer [U-13C]glucose study

1996 • 107 citations

Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase

1998 • 102 citations

Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core

2000 • 95 citations

Evaluation of Isofagomine and Its Derivatives As Potent Glycosidase Inhibitors

1996 • 94 citations

Kinetic and Functional Characterization of 1,4-Dideoxy-1,4-imino--arabinitol: A Potent Inhibitor of Glycogen Phosphorylase with Anti-hyperglyceamic Effect in ob/ob Mice

2000 • 91 citations

The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 Å resolution and 100 K: The role of the water structure and its contribution to binding

1998 • 90 citations

Limitations of the Mass Isotopomer Distribution Analysis of Glucose to Study Gluconeogenesis

1995 • 84 citations

Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1

1998 • 83 citations

Catalytic site of glycogen phosphorylase: structure of the T state and specificity for .alpha.-D-glucose

1982 • 83 citations

Untitled

1998 • 80 citations

Efficient inhibition of muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spiro-thiohydantoin

1999 • 76 citations

The structure of glycogen phosphorylase b with an alkyldihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor

1997 • 74 citations

Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report.

2000 • 71 citations

Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection

1995 • 70 citations

Ternary Complex Crystal Structures of Glycogen Phosphorylase with the Transition State Analogue Nojirimycin Tetrazole and Phosphate in the T and R States^,

1996 • 68 citations

Promoting Early Diagnosis and Treatment of Type 2 Diabetes

2000 • 67 citations

Type II diabetes mellitus.

1998 • 65 citations

Exploding type II

1998 • 63 citations

Demonstration of a Glycogen/Glucose 1-Phosphate Cycle in Hepatocytes from Fasted Rats

1995 • 57 citations

The Relationship Between Cow’s Milk Exposure and Type 1 Diabetes

1996 • 54 citations

Analysis of an allosteric binding site: the nucleoside inhibitor site of phosphorylase a

1982 • 51 citations

Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis and hepatic fatty acid oxidation in NIDDM

1998 • 50 citations

Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401: inhibition and inactivation of glycogen phosphorylase by an activated metabolite.

2000 • 50 citations

A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo

1999 • 49 citations

Inhibition of gluconeogenesis and glycogenolysis by 2,5-anhydro-D-mannitol.

1984 • 44 citations

Regulation of hepatic glucose production in healthy subjects and patients with non-insulin-dependent diabetes mellitus.

1995 • 42 citations

Reducing the burden of diabetes: managing cardiovascular disease

1999 • 42 citations

Regulation of the dephosphorylation of glycogen phosphorylase a and synthase b by glucose and caffeine in isolated hepatocytes

1981 • 42 citations

Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3‐isopropyl 4‐(2‐chlorophenyl)‐1,4‐dihydro‐1‐ethyl‐2‐methyl‐pyridine‐3,5,6‐tricarboxylate

1999 • 41 citations

On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights.

1999 • 40 citations

The effects of isofagomine, a potent glycogen phosphorylase inhibitor, on glycogen metabolism in cultured mouse cortical astrocytes

2000 • 38 citations

Diabetes. Exploding type II.

1999 • 36 citations

Gram-scale synthesis of a glucopyranosylidene-spiro-thiohydantoin and its effect on hepatic glycogen metabolism studied in vitro and in vivo

2000 • 34 citations

Effects of C-1-substituted glucose analogue on the activation states of glycogen synthase and glycogen phosphorylase in rat hepatocytes

1995 • 31 citations

Glucose metabolism and the postprandial state

1999 • 29 citations

A novel anti‐diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

1999 • 28 citations

Limitations of the Mass Isotopomer Distribution Analysis of Glucose to Study Gluconeogenesis

1998 • 27 citations

Glycemic control and cardiovascular disease in Type 2 diabetes: a review

1999 • 27 citations

Estimating gluconeogenesis with [U-¹³C]glucose: molecular condensation requires a molecular approach

1999 • 25 citations

Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs

1997 • 24 citations

The Effect of Glycemic Control on the Incidence of Macrovascular Complications of Type 2 Diabetes

1998 • 22 citations

2 Hepatic glucose metabolism and insulin resistance in NIDDM and obesity

1993 • 21 citations

The effect of caffeine and caffeine analogs on rat liver phosphorylase a activity.

1997 • 21 citations

Glycogen: its mode of formation and contribution to hepatic glucose output in postabsorptive humans

1994 • 17 citations

Measurement of gluconeogenesis and mass isotopomer analysis based on [U-¹³C]glucose

1999 • 16 citations

FDA approach to the regulation of drugs for diabetes

1999 • 13 citations

Uric acid inhibits liver phosphorylaseaactivity under simulated in vivo conditions

2001 • 8 citations

Crucial role of intracellular effectors on glycogenolysis in the isolated rat heart: Potential consequences on the myocardial tolerance to ischemia

1996 • 5 citations

The role of splanchnic glucose appearance in determining carbohydrate tolerance.

1996 • 5 citations

Cardioprotective effect of the glycogen phosphorylase inhibitor CP-380867

2001 • 4 citations

Specificity of inhibition of muscle glycogen phosphorylase b by flavins.

1995 • 3 citations

NMR and Stable Isotope Techniques for Studies of Liver Metabolism in Man

1997 • 2 citations

Metabolic investigations in humans by in vivo nuclear magnetic resonance. Recommendations of ALFEDIAM (French Language Association for the Study of Diabetes and Metabolic Diseases).

1997 • 2 citations

Cited By (0)

Loading...